Amarantus Bioscience Holdings Inc (AMBS)

[breezy1]

AAIC - summary
Quote: "Taken together, we believe this data provides a comprehensive perspective on LymPro. In addition, the Company will be presenting data at our July 31st #C4CT Summit regarding a bridging study in which the Company is comparing Version 1 and Version 2 of LymPro in a head to head study of 72 patients (AD vs. healthy control) to independently reproduce findings from the 2008 Clinical Performance study regarding greater separation in the different cohorts in Version 2 vs. and Version 1. Combined, these four data sets could provide a strong rationale for moving solely to Version 2 of the assay which the Company believes would add tremendous value to LymPro’s diagnostic value." End Quote

- See more at: http://www.thechairmansblog.com/amarantus-bioscience/gerald-commissiong/aaic-2014-understanding-data-presented-lympro-test-version-2/#sthash.UF8BLsDi.xTWl40pt.dpuf